EQS-Adhoc: BB Biotech AG publishes its interim report and revises its dividend policy

EQS-Ad-hoc: BB BIOTECH AG / Key word(s): Results / Half year BB Biotech AG publishes its interim report and revises its dividend policy 24-Jul-2026 / 07:00 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR July 24, 2026 BB Biotech AG publishes its interim report and revises its dividend policy BB Biotech AG (ISIN CH0038389992) today published its interim report as at June 30, 2026, which covers the results of its business activities for the first six months of 2026. Based on the consolidated accounts of BB Biotech AG, a net gain for the period ended June 30, 2026, amounted to CHF 430 mn (loss of CHF 341 mn in H1 2025). In the second quarter, a gain of CHF 451 mn (loss of CHF 100 mn in the corresponding period of the previous year) was incurred. For an investment company, the reported profit reflects the performance of the stocks that it holds in its portfolio. BB Biotech AG has revised its dividend policy with effect from financial year 2026. The company will in future target an annual dividend yield of 3-5%, replacing the previous fixed policy. The interim report as at June 30, 2026, is available under www.bbbiotech.ch. For further information: Bellevue Asset Management AG, Theaterstrasse 12, 8001 Zurich, Switzerland, tel. [phone] Head BB Biotech Team Dr. Christian Koch Head Investor Relations [e-mail] Rachael Burri, [e-mail] Media Relations Fabienne Tresch, [e-mail] www.bbbiotech.ch Company profile  BB Biotech AG is an investment company with its registered office in Schaffhausen/Switzerland and listed on the Swiss and German stock exchanges. It has invested in innovative drug developers headquartered primarily in the US and Western Europe. BB Biotech is one of the world’s largest investors in this sector. The competent Board of Directors with its long-standing experience set the investment strategy and guidelines. Investment decisions are taken by the experienced investment management team of Bellevue Asset Management AG based on their extensive investment research. End of Inside Information 24-Jul-2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. View original content: EQS News

Language:	English
Company:	BB BIOTECH AG
	Schwertstrasse 6
	8200 Schaffhausen
	Switzerland
Phone:	[phone]
E-mail:	[e-mail]
Internet:	www.bbbiotech.ch
ISIN:	CH0038389992
WKN:	A0NFN3
Listed:	Regulated Market in Frankfurt (Prime Standard); Milan, SIX
LEI Code:	391200MBZQNPFHIVKO34
EQS News ID:	2370802

End of Announcement	EQS News Service

2370802  24-Jul-2026 CET/CEST